These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20399057)

  • 1. Characterization of factor VIII pharmaceutical preparations by means of MudPIT proteomic approach.
    Basilico F; Nardini I; Mori F; Brambilla E; Benazzi L; De Palma A; Rosti E; Farina C; Mauri P
    J Pharm Biomed Anal; 2010 Sep; 53(1):50-7. PubMed ID: 20399057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.
    Clifton JG; Huang F; Kovac S; Yang X; Hixson DC; Josic D
    Electrophoresis; 2009 Oct; 30(20):3636-46. PubMed ID: 19768705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a recombinant antihaemophilia-A factor (factor VIII-delta II) by matrix-assisted laser desorption/ionization mass spectrometry.
    Bihoreau N; Veillon JF; Ramon C; Scohyers JM; Schmitter JM
    Rapid Commun Mass Spectrom; 1995; 9(15):1584-8. PubMed ID: 8652881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
    Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display.
    Mühle C; Schulz-Drost S; Khrenov AV; Saenko EL; Klinge J; Schneider H
    Thromb Haemost; 2004 Mar; 91(3):619-25. PubMed ID: 14983240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proteomic approach to the analysis of RNA degradosome composition in Escherichia coli.
    Mauri P; Dehò G
    Methods Enzymol; 2008; 447():99-117. PubMed ID: 19161840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.